Netherlands Pharmaceuticals & Healthcare Q4 2019
We expect the Dutch pharmaceutical market to continue its tedious recovery in 2019 and onwards, with growth slowedby the patent cliff and restrictions on medicine prices under the Medicines Prices Act. We expect innovative drug sales will continueto decline in the short term, with growth in this sub-sector returning over the longer term as the population ages and chronicillnesses rise. However, the government will likely continue to favour lower-value generic medicines as well as other price reducingmeasures as a means of controlling spiralling healthcare costs.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook